Levels of apoptosis induction (4,6-diamidino-2-phenylindole staining, activation of caspase 3) for aminoglycosides were compared by using renal LLC-PK1 cells. Amikacin caused less apoptosis than gentamicin in incubated cells. In electroporated cells, neomycin B and gentamicin caused apoptosis in the 0.03 to 0.1 mM range, isepamicin required larger concentrations (0.2 mM), and amikacin was without effect.
shows data obtained with cells incubated with gentamicin or amikacin. Gentamicin (2 mM [926 mg/liter]) caused a marked, time-dependent increase in the percentage of apoptotic cells (as in reference 5), whereas amikacin (6 mM [3.516 g/liter]) was without effect at days 1 and 2 and caused only a small increase at day 3. Gentamicin also caused a marked increase in caspase 3 activity at day 1, followed by a maximum at day 2 and a decrease thereafter. Caspase 3 activity in cells incubated with amikacin was slightly lower than or similar to that of controls. Apoptosis, measured after 2 days of incubation, proceeded in a concentration-dependent manner with gentamicin (0 to 3 mM [0 to 1.389 g/liter]), whereas amikacin was without a significant effect at concentrations of up to 9 mM (5.274 g/liter). The accumulations of both drugs measured at 48 h were linearly related to their extracellular concentrations, with slopes of 11.9 Ϯ 0.9 nmol ⅐ mg of protein Ϫ1 ⅐ mM Ϫ1 for gentamicin and 7.68 Ϯ 0.51 for amikacin. As a result, cells incubated with amikacin had actually a 1.9-fold-larger drug molar content than those incubated with gentamicin when the values were compared at an extracellular concentration molar ratio of 3:1 (corresponding to their most common dosage ratios for humans, which are 4 mg/kg [8.56 mol/kg] for gentamicin and 15 mg/kg [25.6 mol/kg] for amikacin). Lactate dehydrogenase release (index of necrosis [20] ) remained nonsignificantly different from that from the matching controls under all conditions.
In the next series of experiments, cells were electroporated in the presence of increasing concentrations of neomycin B, gentamicin, isepamicin, or amikacin. As shown in Fig. 2 , neomycin B and gentamicin caused a marked increase in apoptosis for concentrations (during electroporation) spanning between 0.032 and 0.128 mM, with a maximum at 0.064 mM (39.2 mg/liter) for neomycin B and at around 0.1 mM (46.7 mg/liter) for gentamicin (the bell-shaped curve of apoptosis versus concentration is due to the development of necrosis once the concentration reaches a critical threshold; see reference 20 for a discussion). Isepamicin showed a considerably less-marked effect and larger concentrations (between 0.192 and 0.384 mM [109 to 218 mg/liter]) were required. Amikacin was without effect at all concentrations tested (results similar to those described here were obtained with the clinical forms of gentamicin and amikacin; see the supplemental material). The appar-ent cell concentrations for gentamicin and amikacin were determined 1 h after electroporation and were linearly related to their extracellular concentrations (R 2 Ͼ 0.992) but with a larger slope for amikacin than for gentamicin (53.3 Ϯ 1.7 versus 26.7 Ϯ 1.5 nmol ⅐ mg of protein Ϫ1 ⅐ mM Ϫ1 [P Ͻ 0.001]; the slope for gentamicin was similar to that previously reported [20] ).
The present study extends to cultured and electroporated cells our observations made with rats, which showed that amikacin induces less apoptosis than gentamicin when tested at clinically relevant dosages (4). Under our culture conditions, LLC-PK1 cells take up aminoglycosides slowly and to a limited extent (20, 22) , making it necessary to use extracellular concentrations that largely exceed those observed for blood in vivo. Electroporation, a method now widely used for gene transfer and drug delivery in the cytosol of eukaryotic cells without loss of viability (6) (ii) to confirm the low apoptogenic potential of amikacin in comparison with gentamicin, while demonstrating that it is not related to a lower drug accumulation. The common behaviors of neomycin B and gentamicin, on one hand, and of amikacin and isepamicin, on the other hand, suggest specific interactions of these drugs with those intracellular constituents that are susceptible to the triggering of apoptosis (18, 20, 22) . These should be further explored though systematic structure-activity relationship studies, but it already appears that the number of ionizable groups (and perhaps also their positions) could be critical (see the supplemental material). Apoptosis is an established mechanism of renal drug-induced toxicity (21) that develops at lower dosages than necrosis (2, 4, 17) . Although the renal toxicity of aminoglycosides may involve mechanisms other than apoptosis (7, 21) , making clinically pertinent drug ranking quite complex, the method developed here may help in further refining approaches toward the selection of safer derivatives. Generally speaking, it may also prove useful for the study of other drugs which, under normal conditions, would only slowly or poorly reach their intracellular pharmacological or toxicological target. Structure and systematic names of the aminoglycosides studied. Molecules are represented using the chair conformation for each 6-membered cyclic structures (with the forefront bonds in bold), as proposed in [1, 2] , and centered on the 2-deoxystreptamine (for which the numbering of the atoms used in the present representation (and as in [1] ) is indicated). The structures and the configurations were cross-checked using Sci Finder Scholar version 2006 [American Chemical Society, Washington, DC]). The systematic names (obtained from Sci Finder Scholar) start from the left substituent(s) of the 2-deoxystreptamine to continue with the right substituent. The ionizable aminogroups are circled in red.
gentamicin Commercial preparations are a mixture of 3 major (C1, C1a, and C2; approx. molar ratio, 30:15:50) and 2 minor components (C2a, C2b) [3] Average MW used in the present paper: 467 Systematic name of the C1a component: 
Results

Figure SP-2
Comparison between the apoptotic response observed in cells electroporated with gentamicin (left) and amikacin (right) using either a microbiological standard (closed triangles; "microb. st.") or a clinically-used preparation (open squares; "injectable"; preparation complying with the European Pharmacopoeia and available for the corresponding marketing authorization holders in Belgium). Cells were electroporated in the absence (controls) or in the presence of gentamicin (0.03 mM-0.25 mM) or amikacin (0.09-0.9 mM), returned to aminoglycoside-free medium, and apoptotic nuclei enumerated 24 h later. Values are means ± SD (n=3). Statistical analysis (ANCOVA) showed no statistically-significant difference between the respective responses obtained with either type of product source.
